相关实验视频

Updated: Jul 12, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

对晚期青少年鼻血管纤维瘤进行质子疗法

Line Hoeltgen^1,2,3, Thomas Tessonnier^2,4, Eva Meixner^1,2,3

¹Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

|October 28, 2023

概括

质子辐射疗法 (PRT) 为晚期鼻血管纤维瘤 (JNA) 提供了有效的治疗方法,显示出100%的局部控制和最小的急性副作用. 这种先进的辐射技术还显示出与传统光子疗法相比,减少长期并发症的潜力.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

鼻血管纤维瘤 (JNA) 是一种罕见的良性瘤,通常影响青少年男性.
先进的JNA通常需要积极的治疗,因为它有可能导致局部入侵和复发.
目前对晚期JNA的治疗模式可能涉及手术和/或常规光子放射治疗 (XRT).

研究的目的:

报告高级JNA的质子辐射疗法 (PRT) 的初始临床经验.
评估PRT在管理先进的JNA中的有效性和安全性.
为了比较PRT与JNA的螺旋式XRT的剂量测量优势和潜在风险.

主要方法:

对10名晚期JNA患者的回顾性审查,接受PRT治疗 (25个分数中的45 Gy).
在2012年至2022年期间,PRT在最终或术后设置中进行.
对螺旋式XRT计划进行了剂量测量比较和辐射诱导并发症风险估计.

主要成果:

质子辐射疗法 (PRT) 耐受性良好,只有低度的急性毒性 (CTCAE I-II).
实现了100%的局部控制率,随访时间中位数为27个月.
证明了显著的瘤缩,导致5名患者的完全缓解和症状缓解.
与XRT相比,PRT在关键的大脑亚结构中产生了有利的剂量测量,这表明与XRT相比,神经认知障碍和中枢神经系统恶性病的风险降低了.

结论:

质子辐射疗法 (PRT) 是晚期JNA的有效治疗方法.
PRT与最小的急性发病率有关.
与XRT相比,PRT具有减少长期辐射诱导并发症的潜力.

关键词:

在NTCP中,NTCP是NTCP.青少年鼻血管纤维瘤 (JNA)晚期影响后期影响神经认知障碍是一种神经认知障碍.儿科儿科儿科儿科质子辐射疗法质子辐射疗法辐射疗法辐射疗法二次性癌症二次性癌症

更多相关视频

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...